The Journal.

For years, Moderna was a one-hit wonder, a company that bet everything on mRNA, struck gold with a COVID vaccine and then watched its stock crater as the pandemic faded. Now, the company may have found a way to fight skin cancer. An experimental mRNA-based vaccine succeeded in pr ...  Afficher plus

For years, Moderna was a one-hit wonder, a company that bet everything on mRNA, struck gold with a COVID vaccine and then watched its stock crater as the pandemic faded. Now, the company may have found a way to fight skin cancer. An experimental mRNA-based vaccine succeeded in pr ...  Afficher plus

Yesterday, Meta reached a settlement in a landmark social media lawsuit. The tech giant struck a deal with 48 states to pay $18 billion and make changes to the way teens can use Facebook and Instagram. WSJ’s Meghan Bobrowsky explains what this decision means for the future of soc ...  Afficher plus

The U.S. and Canada are once again embroiled in a fight over tariffs. During negotiations last week, President Trump threatened big hikes. Canada retaliated with their own tariffs. WSJ’s Gavin Bade explains how trade negotiations between two countries broke down and what could co ...  Afficher plus

Yesterday, the Trump administration announced a new strategy in the war against Iran that targets the regime’s remaining economic lifelines. Treasury Secretary Scott Bessent called it an “economic D-Day.” WSJ’s Brian Schwartz explains the U.S.’s new sanctions approach and analyze ...  Afficher plus

Customers of the meal kit company Blue Apron have been complaining about canceled orders, missing ingredients and incomplete recipes. The company even acknowledged in a social media post that "recent orders have fallen short." What's behind this mess? WSJ's Sarah Nassauer breaks ...  Afficher plus